Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be male or female and at least 18 years of age.~* Female patients must be of:~* Non-childbearing potential;~* Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.~* 4 to 8 AK lesions on non-head locations.~Exclusion Criteria:~* Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.~* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.~* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEP005 (ingenol mebutate) Gel (Type: ACTIVE_COMPARATOR): PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
- Vehicle gel (Type: PLACEBO_COMPARATOR): Vehicle gel once daily for 2 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).